Why Have Procter & Gamble and Pfizer Missed the Dow's Run to 17,000?

During the past eight months, the Dow has jumped 1,000 points; but these two stocks have fallen. Find out why.

Jul 3, 2014 at 6:00PM

On Thursday, the Dow Jones Industrials (DJINDICES:^DJI) closed above the 17,000 level for the first time, as a surge in job creation, and an unexpected drop in the unemployment rate, made investors more comfortable about the strength of the economic recovery. Since hitting 16,000 for the first time last November, the Dow has seen the pace of its rise slow somewhat; yet more than two dozen of its components have contributed positively to its advance. For Procter & Gamble (NYSE:PG) and Pfizer (NYSE:PFE), however, the road to Dow 17,000 has been paved with modest losses, as the two stocks have faced their own challenges that have kept shareholders from sharing in the Dow's good fortune.

PG Total Return Price Chart

Total Return Price data by YCharts

Procter & Gamble struggled during the winter months, with the stock declining to its worst levels in the days following its fiscal second-quarter earnings report in late January. During the quarter, organic sales rose by 3%; but adverse currency impacts held net sales flat compared to the year-ago quarter's results. Currencies also prevented the company from growing its profit, and Procter & Gamble's outlook for the full 2014 year for low- to mid-single-digit growth in revenue and earnings per share was relatively sluggish compared to valuations that give the stock an earnings multiple of more than 21. Fiscal third-quarter results announced in April raised similar growth concerns; but if a strong U.S. dollar finally gives way to a more normal foreign-exchange environment, then Procter & Gamble could see much better results in the future.

Pg
Source: Procter & Gamble.

For Pfizer, meanwhile, much of the attention that the drug giant has gotten recently has come from its failed attempt to buy out British drugmaker AstraZeneca. Investors had liked the potential merger, not only because of the opportunity to merge drug pipelines and create synergies to reduce costs, but also because the merged company could have reaped substantial tax savings for Pfizer's business operations by adopting a U.K. tax home. In the end, however, AstraZeneca rejected multiple offers from Pfizer, indicating that the British company is only willing to combine at the highest possible price. That could be too much for Pfizer to pay, even for the extensive benefits available from the combination. Pfizer has plenty of prospects for success even without a merger, though, with drugs like its palbociclib breast-cancer treatment drawing positive attention from investors. With the potential to revisit a merger after six months, Pfizer has time to assess its own situation, and decide what to do later in the year.

The Dow's march to 17,000 has been relatively fast, and it's not surprising that it left a few stocks behind. With Pfizer and Procter & Gamble both having promising futures, you shouldn't count them out as the Dow continues to strive for further gains.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not only how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you'll need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. CLICK HERE NOW.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Procter & Gamble. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers